DRI Healthcare (DHTRF)
OTHER OTC:DHTRF
DHTRF Stock Chart & Stats
$12.42
--
Market closed
$12.42
--
Day’s Range― - ―
52-Week Range$9.21 - $13.93
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$681.95M
Enterprise Value$1.11B
Total Cash (Recent Filing)$52.71M
Total Debt (Recent Filing)$457.56M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Jul 30, 2026EPS Estimate
0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding54,959,812
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.06
Price to Sales (P/S)2.38
P/FCF Ratio-40.68
Enterprise Value/Market Cap1.63
Enterprise Value/Revenue5.60
Enterprise Value/Gross Profit26.00
Enterprise Value/Ebitda7.14
Forecast
1Y Price Target
$15.06Price Target Upside21.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)2.34
Revenue Forecast (FY)$188.84M
Bulls Say, Bears Say
Bulls Say
Recurring Royalty Business ModelA royalty-based model yields contractually linked cash flows tied to drug sales, creating recurring, long-duration revenue without operating manufacturing exposure. This capital-light structure supports durable cash generation and scalable portfolio growth over multi-quarter horizons, insulating core cashflow from operational cyclicality.
Revenue MomentumMeaningful TTM revenue growth indicates improving underlying drug sales tied to the royalty portfolio. Sustained top-line momentum strengthens forward royalty receipts, helps stabilize coverage of fixed obligations, and provides a clearer runway to convert growth into persistent distributable cash over the next several quarters.
Positive Operating Cash FlowConsistently positive and improving operating cash flow supports liquidity and debt servicing without relying solely on equity raises. For a royalty owner, operating cash conversion is critical; durable OCF underpins the ability to fund acquisitions, maintain distributions, and withstand short-term volatility in individual drug sales.
Bears Say
Persistent Net LossesDeep, persistent net losses undermine retained earnings and limit internal capital for new royalty purchases or shareholder distributions. Over multiple quarters this forces reliance on external financing for growth, increases vulnerability to market funding stress, and raises doubt about sustainable profitability without structural improvement.
Increased LeverageDebt roughly equal to equity reduces balance-sheet flexibility and raises fixed interest obligations. Higher leverage amplifies downside risk if royalty receipts decline, constrains capacity to bid for attractive royalty assets, and can pressure credit metrics over the medium term, limiting strategic optionality.
Thin Or Negative Free Cash FlowThin or negative free cash flow limits the company's ability to self-fund acquisitions, cover capital needs, or smooth distributions without raising external capital. This structural constraint reduces resilience to shocks in drug sales and increases the importance of maintaining access to financing at reasonable terms.
DRI Healthcare News
DHTRF FAQ
What was DRI Healthcare’s price range in the past 12 months?
DRI Healthcare lowest stock price was $9.21 and its highest was $13.93 in the past 12 months.
What is DRI Healthcare’s market cap?
DRI Healthcare’s market cap is $681.95M.
When is DRI Healthcare’s upcoming earnings report date?
DRI Healthcare’s upcoming earnings report date is Jul 30, 2026 which is in 36 days.
How were DRI Healthcare’s earnings last quarter?
DRI Healthcare released its earnings results on May 14, 2026. The company reported $0.659 earnings per share for the quarter, beating the consensus estimate of $0.565 by $0.094.
Is DRI Healthcare overvalued?
According to Wall Street analysts DRI Healthcare’s price is currently Undervalued.
Does DRI Healthcare pay dividends?
DRI Healthcare does not currently pay dividends.
What is DRI Healthcare’s EPS estimate?
DRI Healthcare’s EPS estimate is 0.55.
How many shares outstanding does DRI Healthcare have?
DRI Healthcare has 54,959,812 shares outstanding.
What happened to DRI Healthcare’s price movement after its last earnings report?
DRI Healthcare reported an EPS of $0.659 in its last earnings report, beating expectations of $0.565. Following the earnings report the stock price went down -2.668%.
Which hedge fund is a major shareholder of DRI Healthcare?
Currently, no hedge funds are holding shares in DHTRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DRI Healthcare Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.06 (21.27% Upside)
$15.06 (21.27% Upside)
Insider Transactions
Bought Shares
Worth $71.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.11%
12-Months-Change
Fundamentals
Return on Equity
-10.93%
Trailing 12-Months
Asset Growth
-7.64%
Trailing 12-Months
Company Description
DRI Healthcare
DRI Healthcare Trust is dedicated to the management and expansion of its diverse collection of pharmaceutical royalty assets. The company's holdings currently encompass 18 royalty streams, which are generated from the sales of 14 distinct pharmaceutical medications spanning eight different therapeutic fields. Established in 2020, its principal operations are based in Toronto, Canada.
DHTRF Stock 12 Month Forecast
Average Price Target
$15.06
▲(21.27% Upside)
Ownership Overview
0.38% Insiders
<0.01% Mutual Funds
― Other Institutional Investors
99.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---